In many developing countries it is a difficult and complex challenge
to ensure that sufficient treatment is made available for all. It is
our goal to develop better medical solutions that can radically
improve the lives of people with diabetes, haemophilia and other conditions.
We therefore depend on efficient protection of our intellectual
property rights. We aim to ensure that our innovations contribute to
better health for people across the world.
We are the largest provider of human insulin worldwide. Human
insulin is an essential drug on the WHO
Model List of Essential Medicines and has been off patent for
many years. This means human insulin is in the public domain and can
be manufactured in any part of the world without the need of a license
to any patents.
We make human insulin available to the world's least developed
countries - LDCs (as defined by the United Nations) through our Access to Insulin
Commitment where human insulin is offered at a maximum of 20% of
the realised price in Europe, the US, Canada and Japan. In many other
low- and middle-income countries, we sell human insulin at equally low
prices through large government tenders reaching millions of people
with diabetes. As a consequence, we do not view non-exclusive
voluntary licensing as the appropriate tool to ensure access to
essential diabetes medicines like human insulin.